When and how to use rituximab in B-cell lymphoproliferative diseases.
| When . | How . |
|---|---|
| With first line chemotherapy in curable B-cell lymphomas | 375 mg/m2 on d1 of each chemotherapy cycle |
| With chemotherapy in rituximab-naïve indolent lymphomas requiring rapid response | 375 mg/m2 on d1 of each chemotherapy cycle |
| As a single agent for grade I-II follicular lymphoma with FLIPI low-intermediate, not in need of a rapid response | 375 mg/m2 weekly x 4, then 375 mg/m2 every 3 months for 1–2 years |
| As a single agent for any type of lymphoma requiring therapy, but unsuitable for chemotherapy (e.g., age, co-morbidity, refusal) | 375 mg/m2 weekly x 4, then 375 mg/m2 every 3 months for 1–2 years |
| When . | How . |
|---|---|
| With first line chemotherapy in curable B-cell lymphomas | 375 mg/m2 on d1 of each chemotherapy cycle |
| With chemotherapy in rituximab-naïve indolent lymphomas requiring rapid response | 375 mg/m2 on d1 of each chemotherapy cycle |
| As a single agent for grade I-II follicular lymphoma with FLIPI low-intermediate, not in need of a rapid response | 375 mg/m2 weekly x 4, then 375 mg/m2 every 3 months for 1–2 years |
| As a single agent for any type of lymphoma requiring therapy, but unsuitable for chemotherapy (e.g., age, co-morbidity, refusal) | 375 mg/m2 weekly x 4, then 375 mg/m2 every 3 months for 1–2 years |